Orgenesis Inc. (ORGS)
NASDAQ: ORGS · IEX Real-Time Price · USD
0.628
-0.021 (-3.19%)
Jul 2, 2024, 4:30 PM EDT - Market closed
Orgenesis Revenue
Orgenesis had revenue of $529.00K in the twelve months ending March 31, 2024, down -98.17% year-over-year. Revenue in the quarter ending March 31, 2024 was $141.00K, a -0.70% decrease year-over-year. In the year 2023, Orgenesis had annual revenue of $530.00K, a decrease of -98.53%.
Revenue (ttm)
$529.00K
Revenue Growth
-98.17%
P/S Ratio
56.06
Revenue / Employee
$3,623
Employees
146
Market Cap
29.65M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 530.00K | -35.50M | -98.53% |
Dec 31, 2022 | 36.03M | 523.00K | 1.47% |
Dec 31, 2021 | 35.50M | 27.85M | 363.96% |
Dec 31, 2020 | 7.65M | 3.75M | 96.26% |
Dec 31, 2019 | 3.90M | -14.76M | -79.10% |
Nov 30, 2018 | 18.66M | 8.57M | 84.90% |
Nov 30, 2017 | 10.09M | 3.69M | 57.71% |
Nov 30, 2016 | 6.40M | 3.42M | 115.10% |
Nov 30, 2015 | 2.97M | - | - |
Nov 30, 2014 | 0 | - | - |
Nov 30, 2013 | 0 | - | - |
Nov 30, 2012 | 0 | - | - |
Nov 30, 2011 | 0 | - | - |
Nov 30, 2010 | 0 | - | - |
Nov 30, 2009 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rapid Micro Biosystems | 23.10M |
Streamline Health Solutions | 21.59M |
Bolt Biotherapeutics | 11.32M |
SAB Biotherapeutics | 2.60M |
VYNE Therapeutics | 423.00K |
ORGS News
- 6 weeks ago - Orgenesis Provides Business Update for the First Quarter of 2024 - GlobeNewsWire
- 2 months ago - Orgenesis Provides Year End Business Update - GlobeNewsWire
- 2 months ago - Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility - GlobeNewsWire
- 3 months ago - Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference - GlobeNewsWire
- 3 months ago - Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes - GlobeNewsWire
- 4 months ago - Orgenesis Inc. Announces $2.3 Million Private Placement - GlobeNewsWire
- 4 months ago - Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing - GlobeNewsWire
- 5 months ago - Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic - GlobeNewsWire